| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1a topline data readout example | TX2100 Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1a | — | Biologics | Rare Diseases | ||
Phase 1a topline data readout example | TX2100 Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1a | — | Biologics | Rare Diseases | ||
Phase 1a topline data readout example | TX2100 Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1a | — | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
Tectonic Therapeutic, Inc. Common Stock$29.95
-0.11 (-0.37%)
D 32Pipeline Score Richly Valued Biotech · Clinical
Market Cap
576.82 M
EPS
-4.04
P/E Ratio
-7.6 $
Value Trade
3.71 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
20.87 M
Operating CF
-18.41 M
Total Assets
246.58 M
Total Liabilities
16.16 M
Equity
230.42 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
236.89 M
Monthly Burn
6.14 M
Runway
37.2 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
50.31 K
52 Week Range
14.39 - 36.03
% held by Insiders
49.76 %
% held by Institutions
62.9 %
Enterprise Value
323.71 M
Total Shares
18.78 M
Short %
24.69 %
Float Shares
9.88 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $60M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 40%
Micro Cap (rank 544 of 905)
Percentile RankTectonic Therapeutic, Inc. Common Stock faces pipeline headwinds (32/100), with $151M risk-adjusted pipeline value, led by TX000045- Dose A in Pulmonary Hypertension (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TX000045- Dose A Small molecule | Pulmonary Hypertension | Phase 2 | NCT06616974 | 9% | $151M | RECRUITING | 180 | STALLED | D (25) | Nov 1, 2026 | ELEVATED_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TECX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Tectonic Therapeutic, Inc. Common Stock (TECX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TECX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TECX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TECX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TECX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TECX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TECX
Jun 10, 2026Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic has completed enrollment for its APEX Phase 2 clinical trial, which evaluates the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients across 14 countries, focusing on a severe subtype of the disease. Topline results are anticipated in early Q1 2027.
Read more →-TECX
May 7, 2026Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic reported its Q1 2026 financial results, highlighting significant progress in its clinical trials, including the nearing completion of patient enrollment for the TX45 APEX Phase 2 trial and the initiation of the TX2100 Phase 1a trial. The company appointed new board members to strengthen governance and reported a cash position of $236.9 million, expected to sustain operations through Q4 2028. However, the company also noted an increase in net loss and R&D expenses compared to the previous year.
Read more →-TECX
Apr 23, 2026Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Tectonic Therapeutic has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Chutter, a veteran in healthcare investment banking, is expected to leverage her extensive experience to support Tectonic's strategic initiatives and growth. The company is progressing towards becoming a multi-product clinical entity with a promising pipeline.
Read more →-TECX
Mar 2, 2026Tectonic Therapeutic to Participate in March Investor Conferences
Tectonic Therapeutic, a clinical-stage biotech firm, will participate in two investor conferences in March 2026. The company's management will host one-on-one meetings and fireside chats, which will be accessible on their website. Tectonic is focused on developing therapeutic proteins and antibodies targeting GPCRs to address unmet medical needs.
Read more →-TECX
Feb 24, 2026Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic has appointed Dr. François Nader as Chair and Independent Director of its Board, effective April 1, 2026. Dr. Nader, who has over 30 years of experience in biotechnology, will succeed Terry McGuire, who will remain on the board until the 2026 Annual Meeting. This leadership change is expected to enhance Tectonic's strategic direction and growth in GPCR-targeted therapies.
Read more →-TECX
Feb 12, 2026Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
Tectonic Therapeutic is set to host a virtual KOL event on February 24, 2026, to discuss TX2100, a novel GPCR antagonist for treating Hereditary Hemorrhagic Telangiectasia (HHT). The event will feature Dr. Hanny Al-Samkari, who will provide insights into HHT's clinical context and the preclinical evidence supporting TX2100. Tectonic plans to initiate a Phase 1a trial of TX2100 in early 2026.
Read more →Competitive Position
How TECX ranks across every disease it competes inCompetitive Position is a premium feature
See how TECX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial